Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GO OBSERVE in ulcerative colitis
NL-OMON22604Not yet recruiting
- Sponsor
- MSD
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of golimumab in autoimmune colitis, sponsored by MSD. Primary endpoint: Proportion of patients with patient-reported continuous clinical response. Planned start Feb 2017; status: not yet recruiting.
02
Drugs
golimumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON22604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22604.